ESR1 and breast lobular carcinoma: Invasive lobular carcinoma histological subtype (HR: 0.698, 95% CI: 0.503–0.969, P = 0.009), ER positivity (HR: 0.479, 95% CI: 0.366–0.620, P < 0.001), PgR positivity (HR: 0.659, 95% CI: 0.513–0.846, P = 0.010), P = 0.010) and receiving adjuvant endocrine therapy (AET) (HR: 0.540, 95% CI: 0.410–0.712, P = 0.001) predicted longer TTR.